DIAGNOS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.28 CAD | -3.45% |
|
-9.68% | -30.86% |
| Sales 2024 * | 258K 189K 15.11M | Sales 2025 * | 5.83M 4.26M 342M | Capitalization | 21.46M 15.69M 1.26B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 83.2 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.68 x |
| P/E ratio 2024 * |
-5.6
x | P/E ratio 2025 * |
-14
x | Employees | 22 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.77% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -3.45% | ||
| 1 week | -9.68% | ||
| Current month | +19.15% | ||
| 1 month | +12.00% | ||
| 3 months | -15.15% | ||
| 6 months | -37.08% | ||
| Current year | -30.86% |
1 week
0.28
0.32
1 month
0.230.35
Current year
0.230.43
1 year
0.230.59
3 years
0.130.65
5 years
0.100.77
10 years
0.102.00
| Managers | Title | Age | Since |
|---|---|---|---|
André Larente
CEO | Chief Executive Officer | - | 20/09/00 |
| Director of Finance/CFO | - | 30/04/08 | |
| Chief Operating Officer | - | 31/12/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Francis Bellido
BRD | Director/Board Member | - | 26/11/19 |
André Larente
CEO | Chief Executive Officer | - | 20/09/00 |
Vincent Duhamel
CHM | Chairman | 59 | 27/09/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.28 | -3.45% | 61,815 |
| 25/04/24 | 0.29 | -1.69% | 28,500 |
| 24/04/24 | 0.295 | -1.67% | 45,500 |
| 23/04/24 | 0.3 | +1.69% | 51,337 |
| 22/04/24 | 0.295 | -4.84% | 105,500 |
Delayed Quote Toronto S.E., April 26, 2024 at 08:43 pm
More quotes
DIAGNOS Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for modifying and developing of applications, such as Computer Assisted Retina Analysis (CARA). CARAâs image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. Its geographical areas include Canada, the United States, Saudi Arabia, Mexico, Costa Rica and Chile. The Companyâs subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.
Sector
IT Services & Consulting
Calendar
05/06/2024
- Q4 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.28
CAD
Average target price
1.5
CAD
Spread / Average Target
+435.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.86% | 15.68M | |
| -12.23% | 194B | |
| +0.74% | 166B | |
| +2.19% | 153B | |
| +4.34% | 99.85B | |
| +7.04% | 77.56B | |
| +19.09% | 73.55B | |
| -7.30% | 71B | |
| -20.54% | 52.81B | |
| +0.53% | 47.86B |
- Stock Market
- Equities
- ADK Stock
